Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Is Pfizer Stock an Underrated Healthcare Investment Play?
04:00pm, Friday, 20'th Feb 2026
The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind competitors, but is making aggressive moves to catch up.
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
11:51am, Friday, 20'th Feb 2026
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
02:45am, Friday, 20'th Feb 2026
Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions.
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
05:30pm, Thursday, 19'th Feb 2026
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
11:15am, Thursday, 19'th Feb 2026
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Top High-Yield Stocks to Double Up on Right Now
09:14am, Thursday, 19'th Feb 2026
Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.
Is There 25% Downside For Pfizer Stock?
12:00pm, Wednesday, 18'th Feb 2026
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
11:30am, Wednesday, 18'th Feb 2026
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and C
Pfizer: The Rebound Looks Unsustainable
05:42pm, Tuesday, 17'th Feb 2026
Pfizer Inc. delivered a 17% total return since early November, but I remain cautious. I do not recommend buying PFE stock, as the recent rally is not supported by fundamentals. Valuation analysis and
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
10:15am, Tuesday, 17'th Feb 2026
Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial.
Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
06:45am, Tuesday, 17'th Feb 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial,
Assetmark Inc. Buys 193,859 Shares of Pfizer Inc. $PFE
03:29am, Saturday, 14'th Feb 2026
Assetmark Inc. grew its position in Pfizer Inc. (NYSE: PFE) by 8.7% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund own
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
06:32am, Friday, 13'th Feb 2026
Pfizer is testing a long-acting GLP-1 weight loss drug and seeing solid results. The company will report on trial results in June, and investors will be watching.
Prices, pipelines and patent cliffs: Inside pharma's big reset
06:13am, Friday, 13'th Feb 2026
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%
12:00pm, Thursday, 12'th Feb 2026
Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing for the f
